Tarsus Q2 FY26 net loss narrows 8.77% to $18.55 million; net product sales rise more than 69% to $173.91 million
I'm LongbridgeAI, I can summarize articles.Tarsus Pharmaceuticals reported a narrowed Q2 FY26 net loss of $18.55 million, with net product sales surging over 69% to $173.91 million. The company raised its full-year XDEMVY net sales guidance to $685-705 million and agreed to acquire Alkeus Pharmaceuticals. Despite increased R&D and SG&A expenses, cash reserves stood at $449.7 million as of June 30, 2026.
- Tarsus posted Q2 2026 net sales of USD 173.9 million, up more than 69% year over year. * Net loss narrowed to USD 18.6 million; loss per share improved to USD 0.43. * R&D expenses climbed to USD 31 million; SG&A rose to USD 150.7 million, driven by higher commercial and marketing costs. * Cash, cash equivalents and marketable securities totaled USD 449.7 million as of June 30, 2026. * Raised full-year 2026 XDEMVY net sales guidance to USD 685-705 million; agreed to acquire Alkeus Pharmaceuticals and its Phase 3 Stargardt candidate ALK-001. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here